GINS2 Is Downregulated in Peripheral Blood of Patients with Intervertebral Disk Degeneration and Promotes Proliferation and Migration of Nucleus Pulposus Cells

Haitao Jiang, Hailang Sun, Jian Dai, Cheng Zhang, and Xiaoming Tang

Department of Orthopedics, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, 223300 Jiangsu, China

Correspondence should be addressed to Xiaoming Tang; dr_tangxiaoming@outlook.com

Received 8 August 2022; Revised 15 August 2022; Accepted 18 August 2022; Published 1 September 2022

Academic Editor: Min Tang

Copyright © 2022 Haitao Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

GINS complex subunit 2 (GINS2) regulates the migration, invasion, and growth of cells in many malignant and chronic diseases. In the present study, we aimed to investigate the expression of GINS2 in the peripheral blood and nucleus pulposus (NP) cells of patients with intervertebral disk degeneration (IDD). GINS2 expression was detected using bioinformatics tools from the GEO public repository and validated using peripheral blood samples from IDD patients and healthy participants. GINS2 clinical significance was explored by the receiver operating curve (ROC) utilizing area under the curve (AUC). Moreover, the influences of GINS2 on cell viability, migration, and invasion were explored by MTT, wound healing, and transwell assays, whereas cell apoptosis was determined by flow cytometry. Expression levels of GINS2 in the peripheral blood were significantly lower in IDD patients than in healthy participants. Moreover, ROC obtained a significantly higher AUC of GINS2 in IDD patients. Further, overexpressed GINS2 increased the proliferation, migration, and invasion of NP cells while overexpressed GINS2 decreased the apoptotic property of cells compared to the NC plasmid and control groups. In conclusion, GINS2 might be a potential therapeutic target of IDD.

1. Introduction

Intervertebral disk degeneration (IDD) is a leading factor of discogenic lower back pain (LBP) [1–3]. IDD has been relegated to the disc tissue-based age-related process due to the continuously decreasing concentration of proteoglycan, which leads to decreased intervertebral height, the production of osteophytes, and endplate sclerosis [4, 5]. A normal human intervertebral disc is a fibrocartilaginous structure made of three main components, such as (1) cartilage end-plates [6, 7]; (2) the annulus fibrosus (AF), composed of type I collagen and fibroblast-like cells [8]; and (3) nucleus pulposus (NP) originated of chondrocyte-like cells [9, 10]. Previous studies have found that the inherited factors were directly linked to the pathogenic factors (almost 70%) that were associated with IDD [11–13]. Thus, assessing the IDD mechanism from a genetic standpoint is crucial to address the present clinical concerns about chronic LBP.

GINS complex subunit 2 (GINS2), a member of the GINS family that also includes GINS2, GINS3, and GINS4 [14], plays an essential role in the DNA duplication [15]. Downregulation of GINS2 suppressed the growth of breast cancer cells by triggering endogenous DNA damage [16, 17]. Further, a study reported that unregulated expression of GINS2 initiated free survival of distant metastasis and therapeutic resistance of endocrine in patients with breast cancer [18]. Meanwhile, upregulated GINS2 urged the proliferation of HL60 cells in acute promyelocytic leukemia [19]. Moreover, overexpressed GINS2 promoted cell migration and proliferation and repressed apoptosis in lung cancer cell lines [20]. Nonetheless, the role of GINS2 in the peripheral blood and NP cells of patients with intervertebral disk degeneration (IDD) remains unknown.

In this study, we found that GINS2 was downregulated in the peripheral blood and NP cells of IDD patients and had a significant diagnostic value for IDD. Moreover, we...
confirmed the promotive effects of GINS2 overexpression on the proliferation, migration, and invasion and the inhibitory effect on the apoptosis of NP cells. Our study might provide a novel target for IDD therapy.

2. Materials and Methods

2.1. Study Design. The present study is aimed at evaluating the GINS2 protein-coding gene expression using a GEO-based repository and further validates it retrospectively in the peripheral blood samples of IDD patients and healthy participants. Subsequently, the expression of GINS2 was achieved in IDD patients. Finally, GINS2 expression and its biological functions were analyzed in vitro using NP cells.

2.2. Enrollment of Patients. 60 participants with IDD (n = 30) and healthy control (n = 30) were retrospectively collected, along with the peripheral blood samples. The subjects were enrolled from June 2020 to June 2021.

2.3. Cell Culture and Cell Transfection. Human NP cells (CP-H170, Procell, Hubei, China) were used in the present study. Herein, cells were cultured in Roswell Park Memorial Institute (RPMI-1640) medium (Thermo Fisher Scientific, MA, USA) comprising 10% fetal bovine serum (FBS, Gibco, NY, USA) and penicillin in a 37°C and 5% CO2 incubator. Furthermore, the cells were seeded onto a 12-well plate. GINS2-overexpression (GINS2-OE) plasmid, negative control (NC) plasmid, and blank control were transfected into NP cells by Lipofectamine 3000 (Invitrogen, CA, USA) for 48 h. They were bought from GenePharma Biotechnology Co. Ltd., (Shanghai, China). Then, all the cells were obtained and utilized for subsequent experiments.

2.4. RNA Extraction. Total RNA was isolated from the whole blood cells of the peripheral blood samples utilizing phenol-chloroform solutions after handling the homogenization by guanidine isothiocyanate (kit for preparing TRizol RNA, Thermo Fisher Scientific, Waltham, MA, USA). RNA concentrations were analyzed by a spectrophotometer (ND1000, NanoDrop Technologies, DE, USA).

2.5. RT-qPCR. Total RNA was isolated from the peripheral blood specimens by following TRizol reagent protocols after transfection. Then, using the reverse transcript kit, the total RNA was reverse-transcribed to cDNA (Sangon Biological Engineering Co., Shanghai). Reaction steps of qPCR were carried out using SYBR Green PCR Master Mix (Applied Biosystems, USA) as follows: (1) for 10 min at 95°C (pre-denaturation); (2) for 15 s at 95°C (denaturation), for 15 s at 60°C (annealing), and for 20 s at 72°C (elongation); and (3) for 15 min at 72°C. At 4°C, reactions were discontinued. For each specimen, these three steps were followed, and a quantitative analysis of the data was performed based on a 2−ΔΔCT value. The RT primers utilized were as follows: GINS2, forward: 5′-AGGGCCAGAGGGGACATGGAC-3′ and reverse: 5′-CATCTCTGCGTGTGCTGGCC-3′; β-actin, forward: 5′-GAGCCGGCTACAGCTT-3′ and reverse: 5′-TCCTTAATGTCAAGCAGATT-3′.

2.6. Microculture Tetrazolium (MTT) Assay. MTT assay was carried out to evaluate the proliferation activity of the cell by following the manufacturer’s protocols (Beyotime Biotech., Shanghai, China) [21]. NP cell lines were cultivated in 96-well plate at 5 × 104 cells/well density and then treated with overexpression of the GINS2 plasmid. 10 μL MTT reagent (Beyotime Biotech., Shanghai, China) was imparts into the well and further incubated for 4 h at 37°C. Each well’s optical density (OD) value was evaluated by a microplate reader (Promega Corporation, Madison, WI, USA) at 490 nm. Results of the cell viability from three independent experiments were normalized to the control group and expressed as mean ± SD.

2.7. Transwell Assay. Matrigel was equally spread on the transwell chamber’s bottom surface (Corning, Shanghai, China). After 10% FBS, 500 μL medium was put into the lower chamber, and 2 × 104 cells were added to the upper chamber. Then, cells on the upper surface were gently scraped, whereas the invasive cells on the lower surface were fixed and colored with crystal violet, followed by observation using a microscope (Olympus Corporation, Tokyo, Japan).

2.8. Wound Healing Assay. After the transfection of NP cells, the cells were treated with trypsin, planted into the 6-well plate, and cultivated till they reached 80% confluence of the medium. Then, the sterile pipette (200 μL) tip was used to scratch each well and washed with PBS solution numerous times to abolish cell debris. In the following 48 h, cells were incubated in medium (serum-free), and migrated cells to the surface of the wound were counted as fabricating an in vitro healing process. The display images of the wound healing assay were obtained by a light microscope (Olympus Corporation, Tokyo, Japan; magnification ×100), and the closure rate was evaluated. The relative ability of migratory cells was assessed by ImageJ software using the width at 0 h time point ((width of wound (0 − 24 h))/0 h width of wound) × 100%.

2.9. Apoptosis Assay. The cells were put into a 12-well plate after transfection, and NP cells were obtained from trypsin digestion without EDTA (Thermo Fisher, Waltham, MA, USA). The rate of apoptotic cells was evaluated by Annexin V-PE/7-AAD (Sungene Biotech., Tianjin, China) following the manufacturer’s protocols and instructions. Herein, cells were stained using 5 μL Annexin V-phycocerythrin (PE) and 5 μL 7-amino-actinomycin D at 37°C for 10 min. The cells were determined by flow cytometry (BD Aria III, New Jersey, USA).

2.10. Western Blotting. After 48 h posttransfection, the cells were kept in a 6-well plate and managed under suitable conditions. After the cells were put into the RIPA assay buffer (Beyotime Biotech., Shanghai, China), protein in equal amounts was parted by SDS-PAGE and transferred onto PVDF membranes (Bio-Rad, CA, USA). Then, the membranes were blocked with skim milk (5%), cleansed with Tris-buffered saline, and incubated with primary antibodies, GINS2 (1:200, ab197123, Abcam, MA, USA) and GAPDH (1:1000, 5174T, Cell Signaling Technology, MA, USA),
Figure 1: Continued.
overnight at 4°C. After that, the membranes were incubated with secondary antibody HRP-conjugated goat antirabbit IgG heavy and light (1:2000, ab6721, Abcam) for 1 h. Furthermore, the membranes were analyzed by an ECL reagent (Thermo Scientific Pierce, IL, USA). The protein band was visualized with the internal reference of β-actin.

2.11. Bioinformatics and Statistical Analysis. Bioinformatics tools were used to create box plots, PCA biplots, volcano maps, and heatmaps. By utilizing the GEO database (GSE124272), the enriched signaling pathways were evaluated through the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) databases. GraphPad (version 8, CA, USA) and SPSS software (version 20.0, IL, USA) were used for statistical analysis throughout the study, and all the data were represented as mean ± standard deviation. T-test and one-way and two-way ANOVA analyses were utilized to compare two or more groups. GINS2 clinical significance was explored using the receiver operating curve- (ROC-) based area under the curve (AUC) in the peripheral blood samples. P < 0.05 was contemplated as the threshold for providing statistical significance.

3. Results and Discussion

3.1. Discovery of GINS2 Expression in IDD. Eight microarray datasets of IDD patients compared to healthy controls were obtained from the GEO database (GSE124272) and used to screen for the GINS2 protein-coding gene utilizing bioinformatics tools, resulting in dysregulated expression of genes as determined by box plot, PCA biplot, volcano map, and heatmap analyses (see Figures 1(a)–1(d)). These eight datasets have demonstrated GINS2 expressions individually (see Figure 2(a)). PCA biplots were shown as the quantitative measure of eight microarray datasets (see Figure 2(b)). Based on these biplots of PCA, the present study involved all eight datasets for subsequent analysis. In the box plot, GINS2 expressions were significantly lower in IDD patients contrasted to a healthy group (see Figure 2(c), P < 0.05).

Moreover, the top 20 significant KEGG pathway enrichments in IDD patients and healthy groups based on the up- and downregulated genes were obtained utilizing the KEGG database (see Figure 3(a), P < 0.05). Likewise, significant top 20 GO enriched pathways related to the up- and downregulated genes were achieved using the GO database (see Figure 3(b), P < 0.05).

3.2. Validation and Clinical Significance of GINS2 in IDD Patients. To validate GINS2 expression levels in the peripheral blood from 30 IDD patients and 30 healthy participants, a scatter plot analysis was used. Herein, GINS2 expression was markedly decreased in the peripheral blood samples of IDD patients compared to the healthy group (see Figure 4(a), P < 0.001). Meanwhile, the demographical parameters of IDD patients and healthy participants are represented in Table 1, which showed no significant differences (P > 0.05). The ROC curve of GINS2 yielded a significantly high AUC of 0.8261 (95% confidence interval (CI) = 0.7051 ~ 0.9472,
Figure 2: Discovery of the GINS2 between IDD patients and healthy control group. (a) The expression value of multiple genes observed in IDD patients versus healthy control by each of the eight microarray datasets of the GEO database (GSE124272) in the box plot. (b) PCA biplots of eight microarray datasets showed quality control measures. (c) GINS2 expression was measured in the peripheral blood from two groups of participants by box plots. G1: healthy group; G2: IDD group.
Figure 3: Continued.
Response to protozoan
Response to molecule of bacterial origin
Response to lipopolysaccharide
Response to fungus
Neutrophil mediated cytotoxicity
Neutrophil degranulation
Neutrophil activation involved in immune response
Leukocyte mediated cytotoxicity
Killing of cells of other organism
Interaction with symbiont cells
Defense response to protozoan
Defense response to fungus
Defense response to bacterium
Defense response to Gram-negative bacterium
Killing of cells in other organism involved in symbiotic interaction
Antimicrobial humoral response
Acute inflammatory response
Antibacterial humoral response
Tonic smooth muscle contraction
Spindle organization
Sister chromatid segregation
Regulation of nuclear division
Regulation of mitotic nuclear division
Prostatic bud formation
Nuclear division
Organelle fission
Nuclear chromosome segregation
Negative regulation of nuclear division
Negative regulation of mitotic nuclear division
Mitotic spindle organization
Mitotic sister chromatid segregation
Mitotic nuclear division
Microtubule cytoskeleton organization
Chromosome segregation
Mitotic sister chromatid cohesion
Detection of mechanical stimulus
Centromeric sister chromatid cohesion

Figure 3: GO and KEGG pathway enrichment analysis. (a) The top significant KEGG-enriched pathways of the targeted genes in IDD are demonstrated individually in up- and downregulated manner. (b) The topmost GO enrichment pathways of the targeted genes in IDD are shown in a similar manner.
P < 0.05) in IDD patients (see Figure 4(b)). Thus, the diagnostic values of GINS2 may be used to precisely distinguish between IDD patients and healthy groups and further provide potential significance in diagnosing IDD.

3.3. Cell Proliferation, Migration, and Invasion Effects of GINS2 in NP Cells. The present study evaluated the biological functions of GINS2 by transfecting NP cells with the GINS2-OE and NC plasmids. WB analysis was utilized to determine the expression of GINS2 mRNA in NP cells transfected with NC plasmid, blank group, and GINS2-OE plasmid (see Figures 5(a) and 5(b), P < 0.001). GINS2 mRNA expression was significantly over/upregulated in NP cells following transfection with the GINS2-OE group compared to other groups (P < 0.001). Similarly, the CCK-8 assay demonstrated that the overexpression of GINS2 markedly increased cell viability (see Figure 5(c), P < 0.001), indicating that GINS2 upregulation may promote the proliferation of NP cells.

The migration and invasion abilities of cells are key indicators of tumor metastasis. The current study utilized wound healing and transwell assays to detect the metastatic capability of the tumor. Wound healing assay showed that the GINS2-OE significantly increased and promoted the migratory potential of NP cells when compared to the NC plasmid and blank groups (see Figures 5(d) and 5(e), P < 0.001). Subsequently, a transwell assay was utilized to determine the invasive ability of NP cells, which showed that GINS2-OE significantly promoted the invasion capability of NP cells when compared to other groups (see Figures 6(a) and 6(b), P < 0.001). Hence, the overexpression of GINS2 could promote NP cell migration and invasion.

3.4. Cell Apoptosis Effects of GINS2 in NP Cells. To determine the apoptosis effects of GINS2 in NP cells, Annexin V-PE/7-AAD staining was utilized. The apoptosis assay demonstrated that GINS2-OE significantly decreased the apoptosis rate in NP cells when compared to the NC plasmid and blank groups (see Figures 7(a)–7(d), P < 0.001). Thus, overexpression of GINS2 inhibited NP cell apoptosis.

4. Discussion

IDD is widely recognized as a major cause of LBP, a globally prevalent condition that imposes a vast social-economic burden and degrades the quality of life [22–24]. Disk degeneration is also associated with disk prolapse or herniation and sciatica, though it can be asymptomatic in some cases [25, 26]. In IDD cases, the intervertebral disk height and spinal column-based biomechanics are altered, which can have a significant effect on the behavior of other spinal structures, involving the ligaments and muscles [7]. In the long run, this
Figure 5: The biological mechanism of GINS2 in NP cells. (a, b) Western blot analysis represented the GINS2 mRNA expression in three groups of GINS2-OE, NC plasmid, and blank group. (c) MTT assay showed the cell proliferation or growth rate of three groups in transfected NP cells. (d) The wound healing rate was observed between the three groups. (e) Wound healing assay was performed to evaluate the migratory ability of transfected NP cells. NC plasmid, blank group, and GINS2-OE.
condition can progress to spinal stenosis [27], which is the main reason for pain and disability in the aged population [25]. Overall, IDD is a tangled process whose mechanism is not fully apprehended. Extracellular matrix degeneration, mechanical loading, extreme senescence, incremental secretions of inflammatory factors, and NP cell aberrant apoptosis have all been implicated in the development of IDD [28–32]. Thus, current research into NP cell apoptosis and targeted interventions may not only anticipate significant therapeutic strategies but also increase the underlying pathogenetic mechanisms of IDD.

GINS2 takes a crucial part in the replication activity and chromatin binding due to the complex structure as a heterotetramer [33]. In malignant cancers, such as cervical cancer, GINS2 was significantly upregulated in cancer cells and tumor tissues with an inverse correlation to overall survival in cervical cancer patients [34], whereas in thyroid cancer, GINS2 overexpression initiated the cancer cell proliferation and suppressed the apoptosis via LOXL2 and CITED2 mediation [35, 36]. Our study determined and confirmed the dysregulation of GINS2 expression in the peripheral blood samples from IDD patients and healthy participants. Our pathway enrichment analysis results indicated that GINS2 protein-coding gene significantly differentiated IDD patients from the healthy group by representing an AUC of 0.8261. Thus, GINS2 protein-coding gene not only played a role in IDD pathogenesis but may also serve as a novel diagnostic biomarker for IDD by distinguishing IDD patients from healthy controls.

GINS2 was previously shown to influence the proliferation, migration, and invasion of non-small-cell lung cancer cells via PI3K/Akt and MEK/ERK signaling pathways [37]. Similarly, interfering with GINS2 inhibited cell viability, initiated cell cycle arrest, and facilitated apoptosis in pancreatic cancer cell lines using the MAPK/ERK pathway [38]. Our study evaluated the biological functions of GINS2 in NP cells by GINS2-OE and NC plasmids. Herein, consistent with the above-mentioned studies, our in vitro analysis revealed that the overexpression of GINS2 promoted cell proliferation, migration, and invasion of NP cells; meanwhile, it suppressed the apoptotic activity and vice versa. Thus, GINS2 may act as a potential therapeutic target for IDD.

Nonetheless, the current study has a few limitations. At first, the determination of GINS2 was screened using an online database of GEO, which could contain biased microarray results or samples. Second, GINS2 validation was carried out with a smaller size-based cohort; therefore, future studies are needed to carry out validation using a larger size-based cohort. Third, the present study was unable to include more clinical characteristics and risk factors for patients with IDD. Fourth, the GINS2 was evaluated and

![Figure 6: Effects of GINS2 on migration and invasion of NP cells. (a, b) Transwell assay was performed on NP cells and showed the invasive capacity of cells. NC plasmid, blank group, and GINS2-OE.](image-url)
compared using only the peripheral blood samples and NP cell lines without further validation of downregulating signaling pathways. Thus, future research is required to thoroughly determine and assess GINS2 in conjunction with other GINS family members, which might be taking part in the occurrence, development, and progression of IDD.

5. Conclusion

In conclusion, downregulation of GINS2 was observed in the peripheral blood and NP cells of IDD patients, which had a significant diagnostic value for IDD. Moreover, our study proved GINS2 overexpression promoted the proliferation, migration, and invasion and inhibited the apoptosis of NP cells, implying the biological role of GINS2 in IDD. GINS2 might be a novel target for IDD therapy.

Data Availability

The datasets used during the current study are available from the corresponding author on request.
Ethical Approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent

Informed consent was obtained from all individual participants included in the study.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

Haitao Jiang and Hailang Sun contributed equally to this work.

References

[1] M. G. Wiet, A. Piscioneri, S. N. Khan, M. N. Ballinger, J. A. Hoyland, and D. Purmessur, “Mast cell-intervertebral disc cell interactions regulate inflammation, catabolism and angiogenesis in discogenic back pain,” Scientific Reports, vol. 7, no. 1, p. 12492, 2017.

[2] V. K. Podichetty, “The aging spine: the role of inflammatory mediators in intervertebral disc degeneration,” Cellular and Molecular Biology (Noisy-le-Grand, France), vol. 53, no. 5, pp. 4–18, 2007.

[3] M. Millecamps and L. S. Stone, “Delayed onset of persistent discogenic axial and radiating pain after a single-level lumbar intervertebral disc injury in mice,” Pain, vol. 159, no. 9, pp. 1843–1855, 2018.

[4] A. G. Hadjipavlou, M. N. Tzermiadianos, N. Bogduk, and M. R. Zindrick, “The pathophysiology of disc degeneration: a critical review,” Journal of Bone and Joint Surgery. British Volume (London), vol. 90, no. 10, pp. 1261–1270, 2008.

[5] P. P. Raj, "Intervertebral disc: anatomy-physiology-pathophysiology-treatment," Pain Practice, vol. 8, no. 1, pp. 18–44, 2008.

[6] H. Liu, H. Kang, C. Song et al., “Urolithin A inhibits the catabolic effect of TNFα on nucleus pulposus cell and alleviates intervertebral disc degeneration in vivo,” Frontiers in Pharmacology, vol. 9, p. 1043, 2018.

[7] L. Pimenta, L. Marchi, L. Oliveira, J. Nogueira-Neto, E. Coutinho, and R. Amaral, "Elastomeric lumbar total disc replacement: clinical and radiological results with minimum 84 months follow-up," Int J Spine Surg, vol. 12, no. 1, pp. 49–57, 2018.

[8] S. Yang, F. Zhang, J. Ma, and W. Ding, "Intervertebral disc age and degeneration: the antiapoptotic effect of oestrogen," Ageing Research Reviews, vol. 57, article 100978, 2020.

[9] F. C. Bach, S. A. de Vries, A. Krouwels et al., “The species-specific regenerative effects of notochordal cell-conditioned medium on chondrocyte-like cells derived from degenerated human intervertebral discs,” European Cells & Materials, vol. 30, pp. 132–147, 2015.

[10] R. Rodrigues-Pinto, A. Berry, K. Piper-Hanley, N. Hanley, S. M. Richardson, and J. A. Hoyland, "Spatiotemporal analysis of putative notochordal cell markers reveals CD24 and keratins 8, 18, and 19 as notochord-specific markers during early human intervertebral disc development," Journal of Orthopaedic Research, vol. 34, no. 8, pp. 1327–1340, 2016.

[11] C. Bijkerk, J. J. Houwing-Duijvestijn, W. Ivan Valkenburg et al., “Heritabilities of radiologic osteoarthritis in peripheral joints and of disc degeneration of the spine,” Arthritis and Rheumatism, vol. 42, no. 8, pp. 1729–1735, 1999.

[12] P. N. Sambrook, A. J. MacGregor, and T. D. Spector, "Genetic influences on cervical and lumbar disc degeneration: a magnetic resonance imaging study in twins," Arthritis and Rheumatism, vol. 42, no. 2, pp. 366–372, 1999.

[13] M. C. Battie, T. Videman, L. E. Gibbons, L. D. Fisher, H. Manninen, and K. Gill, "1995 Volvo Award in clinical sciences. Determinants of lumbar disc degeneration. A study relating lifetime exposures and magnetic resonance imaging findings in identical twins," A study relating lifetime exposures and magnetic resonance imaging findings in identical twins. Spine (Phila Pa 1976), vol. 20, no. 24, pp. 2601–2612.

[14] A. Gambus, R. C. Jones, A. Sanchez-Diaz et al., “GINS maintains association of Cdc45 with MCM in replisome progression complexes at eukaryotic DNA replication forks,” Nature Cell Biology, vol. 8, no. 4, pp. 358–366, 2006.

[15] Y. Kubota, Y. Takase, Y. Komori et al., “A novel ring-like complex of Xenopus proteins essential for the initiation of DNA replication,” Genes & Development, vol. 17, no. 9, pp. 1114–1152, 2003.

[16] J. K. Rantala, H. Edgren, L. Lehtinen et al., "Integrative functional genomics analysis of sustained polyplody phenotypes in breast cancer cells identifies an oncogenic profile for GINS2," Neoplasia, vol. 12, no. 11, pp. 877–891, 2014.

[17] M. Thomassen, K. M. Jochumsen, O. Mogensen, Q. Tan, and T. A. Kruse, “Gene expression meta-analysis identifies chromosomal regions involved in ovarian cancer survival,” Genes, Chromosomes & Cancer, vol. 48, no. 8, pp. 711–724, 2009.

[18] M. Zheng, Y. Zhou, X. Yang et al., "High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammmary cancer stem cells in breast cancer patients," Breast Cancer Research and Treatment, vol. 148, no. 2, pp. 423–436, 2014.

[19] X. Zhang, L. Zhong, B. Z. Liu, Y. J. Gao, Y. M. Gao, and X. X. Hu, "Effect of GINS2 on proliferation and apoptosis in leukaemic cell line," International Journal of Medical Sciences, vol. 10, no. 12, pp. 1795–1804, 2013.

[20] W. Tian, X. Yang, H. Yang, and B. Zhou, "GINS2 functions as a key gene in lung adenocarcinoma by WGCNA co-expression network analysis," Oncotargets and Therapy, vol. Volume 13, pp. 6735–6746, 2020.

[21] J. Zhu, C. Jiang, H. Hui et al., “Overexpressed IncRNA LINC00893 suppresses progression of colon cancer by binding with miR-146b-3p to upregulate PRSS8," Journal of Oncology, vol. 2022, Article ID 8002318, 2022.

[22] M. J. Prince, F. Wu, Y. Guo et al., "The burden of disease in older people and implications for health policy and practice," Lancet, vol. 385, no. 9967, pp. 549–562, 2015.

[23] H. B. Bressler, W. J. Keyes, P. A. Rochon, and E. Badley, "The prevalence of low back pain in the elderly," A systematic review
of the literature. Spine (Phila Pa 1976), vol. 24, no. 17, pp. 1813–1819, 1999.

[24] D. Hoy, C. Bain, G. Williams et al., “A systematic review of the global prevalence of low back pain,” Arthritis and Rheumatism, vol. 64, no. 6, pp. 2028–2037, 2012.

[25] K. Luoma, H. Riihimäki, R. Luukkonen, R. Raininko, E. Viikari-Juntura, and A. Lamminen, “Low back pain in relation to lumbar disc degeneration,” Spine (Phila Pa 1976), vol. 25, no. 4, pp. 487–492, 2000.

[26] S. D. Boden, D. O. Davis, T. S. Dina, N. J. Patronas, and S. W. Wiesel, “Abnormal magnetic-resonance scans of the lumbar spine in asymptomatic subjects. A prospective investigation,” The Journal of Bone and Joint Surgery. American Volume, vol. 72, no. 3, pp. 403–408, 1990.

[27] M. Deng, J. F. Griffith, X. M. Zhu, W. S. Poon, A. T. Ahuja, and Y. X. J. Wang, “Effect of ovariectomy on contrast agent diffusion into lumbar intervertebral disc: a dynamic contrast-enhanced MRI study in female rats,” Magnetic Resonance Imaging, vol. 30, no. 5, pp. 683–688, 2012.

[28] T. Kadow, G. Sowa, N. Vo, and J. D. Kang, “Molecular basis of intervertebral disc degeneration and herniations: what are the important translational questions?,” Clinical Orthopaedics and Related Research, vol. 473, no. 6, pp. 1903–1912, 2015.

[29] K. Gui and Y. Yu, “Research status on molecular basis of intervertebral disc degeneration and repairing effect of platelet-rich plasma,” Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, vol. 29, no. 1, pp. 123–128, 2015.

[30] C. K. Kepler, R. K. Ponnappan, C. A. Tannoury, M. V. Risbud, and D. G. Anderson, “The molecular basis of intervertebral disc degeneration,” The Spine Journal, vol. 13, no. 3, pp. 318–330, 2013.

[31] C. L. Le Maitre, A. J. Freemont, and J. A. Hoyland, “Accelerated cellular senescence in degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc degeneration,” Arthritis Research & Therapy, vol. 9, no. 3, p. R45, 2007.

[32] I. A. Stokes and J. C. Iatridis, “Mechanical conditions that accelerate intervertebral disc degeneration: overload versus immobilization,” Spine (Phila Pa 1976), vol. 29, no. 23, pp. 2724–2732, 2004.

[33] K. Kamada, Y. Kubota, T. Arata, Y. Shindo, and F. Hanaoka, “Structure of the human GINS complex and its assembly and functional interface in replication initiation,” Nature Structural & Molecular Biology, vol. 14, no. 5, pp. 388–396, 2007.

[34] F. Ouyang, J. Liu, M. Xia et al., “GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer,” Oncology Reports, vol. 37, no. 5, pp. 2652–2662, 2017.

[35] Y. Ye, Y. N. Song, S. F. He, J. H. Zhuang, G. Y. Wang, and W. Xia, “GINS2 promotes cell proliferation and inhibits cell apoptosis in thyroid cancer by regulating CITED2 and LOXL2,” Cancer Gene Therapy, vol. 26, no. 3-4, pp. 103–113, 2019.

[36] L. R. Barkley, I. Y. Song, Y. Zou, and C. Vaziri, “Reduced expression of GINS complex members induces hallmarks of pre-malignancy in primary untransformed human cells,” Cell Cycle, vol. 8, no. 10, pp. 1577–1588, 2009.

[37] X. Liu, L. Sun, S. Zhang, S. Zhang, and W. Li, “GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling,” Journal of Cellular Physiology, vol. 235, no. 11, pp. 7747–7756, 2020.

[38] M. Zhang, S. He, X. Ma et al., “GINS2 affects cell viability, cell apoptosis, and cell cycle progression of pancreatic cancer cells via MAPK/ERK pathway,” Journal of Cancer, vol. 11, no. 16, pp. 4662–4670, 2020.